Efficacy and Safety of Repeated Intraarticular Injections of Hyaluronic Acid in Patients With OA of the Knee

Exclusion Criteria

• •Overweight patients (body mass index \> 32).
• •Pregnant and lactating women. Women of child-bearinge age not using effective contraception
• •Patients who have received intra-articular hyaluronic acid within the previous year and/or intra-articular steroids or articular lavage in the chosen knee,within the previous 3 months prior to their inclusion in the study.
• •AINE administration within the 14 days prior to their inclusion in the study.
• •Administration of glucosamine sulphate, chondroitin sulphate and diacerein within the 3 months prior to their inclusion in the study.
• •Immunocompromised patients or patients receiving systemic immunosuppressive therapy.
• •Patients with known sensitivity to HA, parcetamol or AINEs permitted as rescue medication.
• •Patients who have received any investigational drug within 30 days prior to visit 1, or who are scheduled for the administration of an investigational drug other than the protocol product during this study.
• •Patients with severely impaired central nervous system.
• •Patients with coagulation alterations, despite receiving treatment.
• •Patients with secondary osteoarthritis of the knee
• •Patients having previously received surgery, including arthroscopy
• •Patients with articular inflammatory disease